Exelixis, Inc. (NASDAQ:EXEL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Exelixis, Inc. (NASDAQ:EXEL) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $27.43.

Several research firms have commented on EXEL. JMP Securities increased their price target on shares of Exelixis from $27.00 to $29.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 7th. Oppenheimer restated an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Truist Financial reaffirmed a “buy” rating and set a $33.00 price target (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Stephens initiated coverage on Exelixis in a research report on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 price objective for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $27.00 target price on shares of Exelixis in a research report on Wednesday, August 7th.

Exelixis Stock Up 0.0 %

Shares of EXEL stock opened at $26.03 on Monday. The firm has a market cap of $7.43 billion, a price-to-earnings ratio of 40.67, a PEG ratio of 0.50 and a beta of 0.54. Exelixis has a 52-week low of $18.64 and a 52-week high of $27.53. The company’s 50 day moving average is $23.98 and its 200 day moving average is $22.84.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. The business had revenue of $637.18 million for the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Analysts anticipate that Exelixis will post 1.54 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares in the company, valued at $13,024,750. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Exelixis news, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the sale, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 311,145 shares of company stock worth $8,162,943. Insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GAMMA Investing LLC acquired a new position in Exelixis in the 4th quarter worth about $27,000. Truist Financial Corp acquired a new position in shares of Exelixis during the 4th quarter worth approximately $218,000. Victory Capital Management Inc. lifted its position in shares of Exelixis by 132.1% during the 4th quarter. Victory Capital Management Inc. now owns 130,731 shares of the biotechnology company’s stock valued at $3,136,000 after buying an additional 74,410 shares in the last quarter. Fisher Asset Management LLC grew its stake in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 728 shares during the period. Finally, Amalgamated Bank increased its holdings in Exelixis by 3.3% in the 4th quarter. Amalgamated Bank now owns 231,909 shares of the biotechnology company’s stock worth $5,563,000 after acquiring an additional 7,476 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.